PT  - JOURNAL ARTICLE
AU  - Melina Michelen
AU  - Lakshmi Manoharan
AU  - Natalie Elkheir
AU  - Vincent Cheng
AU  - Drew Dagens
AU  - Claire Hastie
AU  - Margaret O’Hara
AU  - Jake C. Suett
AU  - Amanda Burls
AU  - Carol Foote
AU  - Gail Carson
AU  - Piero Olliaro
AU  - Louise Sigfrid
AU  - Charitini Stavropoulou
TI  - Characterising long-term covid-19: a rapid living systematic review
AID  - 10.1101/2020.12.08.20246025
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.08.20246025
4099  - http://medrxiv.org/content/early/2020/12/09/2020.12.08.20246025.short
4100  - http://medrxiv.org/content/early/2020/12/09/2020.12.08.20246025.full
AB  - Objective To understand the frequency, profile, and duration of persistent symptoms of covid-19 and to update this understanding as new evidence emerges.Design A living systematic review produced in response to the rapidly evolving evidence base for ‘long covid’.Data sources Medline and CINAHL (EBSCO), Global Health (Ovid), WHO Global Research Database on covid-19, LitCOVID, and Google Scholar to 28th September 2020.Study selection Studies reporting long-term symptoms and complications among people with confirmed or suspected covid-19, both in those previously hospitalised and those never hospitalised. Only studies incorporating over 100 participants qualified for data extraction and were assessed for risk of bias. Results were analysed using descriptive statistics.Quality assessment Risk of bias was assessed using a quality assessment checklist for prevalence studies.Results Twenty-eight studies qualified for data extraction; 16 of these were cohort studies, ten cross-sectional, and two large case series. The analysis included 9,442 adults with covid-19 from 13 countries. The longest mean follow-up period was 111 (SD: 11) days post-hospital discharge. A wide range of systemic, cardiopulmonary, gastrointestinal, neurological, and psychosocial symptoms was reported, of which the most common were breathlessness, fatigue, smell and taste disturbance, and anxiety. Persistent symptoms were described across both previously hospitalised and non-hospitalised populations. The quality of evidence was low, with a high risk of bias and heterogeneity in prevalence. The incorporated studies demonstrated limited external validity, a lack of control subjects, and inconsistent data collection methods. Few studies were conducted in primary care, no studies focused solely on children, and no studies were set in low- and middle-income countries.Conclusion Our findings suggest that ‘long covid’ is a complex, heterogeneous condition; however, the limited evidence base currently precludes a precise definition of its symptoms and prevalence. There is a clear need for robust, controlled, prospective cohort studies, including different at-risk populations and settings, incorporating appropriate investigations, collected and recorded in a standardised way.Systematic review registration The protocol was prospectively registered on the PROSPERO database (CRD42020211131).Readers’ note This living systematic review will be updated regularly as new evidence emerges. The search terms and inclusion criteria will be updated in line with new evidence, research priorities and policy needs. This version is the original publication. Updates may occur for up to two years from the date of original publication. When citing this paper please consider adding the version number and date of access for clarity.Section 1: What is already known on this topic?A significant number of people continue to describe symptoms long after the acute phase of covid-19 is over, so called ‘long covid’.There is no case definition for ‘long covid,’ which appears to be a heterogeneous condition with an uncertain prevalence.Section 2: What this study addsThis ‘living’ systematic review provides a comprehensive summary of the published evidence on persistent symptoms of covid-19 and will be regularly updated.The breadth of reported symptoms suggests a complex, heterogeneous condition affecting both hospitalised patients and those managed in the community.However, the current evidence base of the clinical spectrum of ‘long covid’ is of limited quality and is vulnerable to biases.Our review identifies those areas where further ‘long covid’ research is critically needed.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. JCS declares he is an individual living with long-term symptoms of probably covid-19. All other authors declare no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135]. The results presented have been obtained with the financial support of the EU FP7 project PREPARE (602525).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethics approval was neededAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available on the paper